Her2-positive breast cancer: herceptin and beyond.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Cancer

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2008.09.013PMID 19022660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

  2009cited by this paper
• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128))

  2008cited by this paper
• CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

  2007cited by this paper
• [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

  2007cited by this paper
• Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy

  2007cited by this paper
• Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy

  2007cited by this paper
• Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer

  2007cited by this paper
• Trastuzumab: triumphs and tribulations

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

  2007cited by this paper
• Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

  2007cited by this paper
• HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

  2007cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

  2007cited by this paper
• The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

  2007cited by this paper
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

  2007cited by this paper
• Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency

  2007cited by this paper
• Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.

  2007cited by this paper
• Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

  2006cited by this paper
• HER2 therapy: Molecular mechanisms of trastuzumab resistance

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy

  2006cited by this paper
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

  2006cited by this paper
• Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

  2005cited by this paper
• Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy

  2005cited by this paper
• The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.

  2005cited by this paper
• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Preclinical testing of an anti-erbB-2 recombinant toxin

  2005cited by this paper
• Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

  2005cited by this paper
• Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.

  2004cited by this paper
• P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

  2004cited by this paper
• Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers

  2004cited by this paper
• Determinants of Rapamycin Sensitivity in Breast Cancer Cells

  2004cited by this paper
• Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

  2004cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• mTOR: a protein kinase switching between life and death.

  2004cited by this paper
• Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors

  2004cited by this paper
• Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

  2003cited by this paper
• Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2

  2003cited by this paper
• Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Mechanism of action of trastuzumab and scientific update.

  2001cited by this paper
• mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats

  2000cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.

  1999cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.

  1994cited by this paper
• Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

  1989cited by this paper
• Proto-oncogenes and human cancers.

  1987cited by this paper

• Quality by Design-Driven Analytical Method for Dual Drug Quantification in Electrospun Nanofibers Coupled with In Silico Targetability Assessment in Breast Cancer

  2026cites this paper
• Targeted metabolomics reveals tricarboxylic acid cycle-related metabolites serve as predictive biomarkers for trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer

  2025cites this paper
• Impact of Chronic Stress and Anxiety on Interleukin-6, Hypoxia-Inducible Factor-1α and on Pathological and Immunohistochemical Parameters in Breast Cancer

  2025cites this paper
• Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

  2025cites this paper
• Comprehensive analysis of Crotalaria willdenowiana DC.: GC–MS profiling, antioxidant and anticancer activities, molecular docking studies, and in silico ADME profiling

  2025cites this paper
• Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development

  2025cites this paper
• Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications.

  2025cites this paper
• Novel Insight into The Warburg effect: Sweet Temptation.

  2025cites this paper
• Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer

  2025cites this paper
• Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types

  2025cites this paper
• An Update on Alkylating Agents in Breast Cancer Therapy

  2025cites this paper
• Multiple Regression Study about Breast Cancer, Implications for all Women, especially Africans and Asians moving to cold, Cloudy Climates

  2025cites this paper
• The HOX Gene Family’s Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors

  2025cites this paper
• Cubosomes functionalized with antibodies as a potential strategy for the treatment of HER2-positive breast cancer.

  2024cites this paper
• Assessment of the Impact of Trace Essential Metals on Cancer Development

  2024cites this paper
• Breast Cancer Therapies: A Review

  2024influential citation
• Refusal of treatment among HER2-positive breast cancer patients in China: a retrospective analysis

  2024cites this paper
• Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients

  2024cites this paper
• Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.

  2024cites this paper
• Encapsulation and release of calcein from herceptin-conjugated eLiposomes

  2024cites this paper
• A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice

  2024cites this paper
• Multicellular spheroids containing synthetic mineral particles: an advanced 3D tumor model system to investigate breast precancer malignancy potential according to the mineral type.

  2023cites this paper
• Systemic Therapy in Elderly Patients With Her2/Neu-Positive Breast Cancer: A SEER Database Study

  2023cites this paper
• Addressing Uncertainty in Imbalanced Histopathology Image Classification of HER2 Breast Cancer: An Interpretable Ensemble Approach With Threshold Filtered Single Instance Evaluation (SIE)

  2023cites this paper
• Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer

  2023cites this paper
• Dual attention model with reinforcement learning for classification of histology whole-slide images

  2023cites this paper
• Microcalcifications can either trigger or suppress breast precancer malignancy potential according to the mineral type in a 3D tumor model

  2023cites this paper
• Design, Synthesis, and In Vitro Mitotic Evaluation of 3‐Amino‐Isoquinolinones as Anticancer Agents

  2022cites this paper
• Molecular targeted therapy for anticancer treatment

  2022cites this paper
• The effect of HIF-1α inhibition in breast cancer cells prior to doxorubicin treatment under conditions of normoxia and hypoxia.

  2022cites this paper
• A Nanoplasmonic Portable Molecular Interaction Platform for High‐Throughput Drug Screening

  2022cites this paper
• Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

  2022influential citation
• The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer

  2022cites this paper
• Regulation of Signaling from the Epidermal Growth Factor Family.

  2022cites this paper
• Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.

  2022cites this paper
• Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment

  2022cites this paper
• Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer

  2022cites this paper
• ORLNC1 suppresses cell growth in HER2 positive breast cancer via miRNA-296 sponging.

  2022cites this paper
• Ligation-free isothermal nucleic acid amplification.

  2022cites this paper
• Current and Future Therapies for Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK—HER2 and VEGFR2 receptors, by in silico approach

  2021cites this paper
• Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy

  2021cites this paper
• Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

  2021cites this paper
• A mathematical model for phenotypic heterogeneity in breast cancer with implications for therapeutic strategies

  2021cites this paper
• Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis

  2021cites this paper
• Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer

  2021cites this paper
• Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis

  2021cites this paper
• Breast Cancer and the Renin-Angiotensin System (RAS): Therapeutic Approaches and Related Metabolic Diseases.

  2021cites this paper
• RNA m6A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer

  2021cites this paper
• CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells

  2020cites this paper
• Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer

  2020cites this paper
• Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition.

  2020cites this paper
• Pharmacological and toxicological activities of the extracts of papaya leaves used traditionally for the treatment of diarrhea

  2020cites this paper
• Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease

  2020cites this paper
• Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy

  2020cites this paper
• Investigation of The Synergistic Effects of Trastuzumab And Gambogic Acid in Her-2 Positive Breast Cancer Cell Line

  2020cites this paper
• Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

  2020cites this paper
• Detection of HER2 from Haematoxylin-Eosin Slides Through a Cascade of Deep Learning Classifiers via Multi-Instance Learning

  2020cites this paper
• Regulation and New Treatment Strategies in Breast Cancer.

  2019cites this paper
• Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines

  2019cites this paper
• Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer

  2019cites this paper
• Phospholipase-Cγ1 Signaling Protein Down-Regulation by Oligoclonal-VHHs based Immuno-Liposome: A Potent Metastasis Deterrent in HER2 Positive Breast Cancer Cells

  2019cites this paper
• In vitro effects of Jia-Wei-Xiao-Yao-San in human breast cancer cells treated with Trastuzumab

  2019cites this paper
• Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations.

  2019cites this paper
• Functionalized Porous Membranes for Rapid Protein Capture and Digestion Prior to Mass Spectrometry Analysis

  2018cites this paper
• Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer

  2018cites this paper
• Development of Natural Cyclic Peptide Inhibitors of XRCC4/XLF Interaction for Radio-Sensitization of Breast Tumor Cells

  2018cites this paper
• Anti-oxidation properties of leaves, skin, pulp, and seeds extracts from green papaya and their anti-cancer activities in breast cancer cells

  2018cites this paper
• Mechanism of action of the trastuzumab biosimilar CT-P6

  2018cites this paper
• Cancer Immunotherapy: The Dawn of Antibody Cocktails.

  2018cites this paper
• HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy

  2018cites this paper
• Determination of HER-2/neu gene Status by Chromogenic in Situ Hybridisation Assay on Borderline (2+) Immunohistochemistry Cases in Patients with Invasive Breast Carcinoma: An Experimental Study on Preserved Tissue

  2018cites this paper
• Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.

  2018cites this paper
• Regulation of Human Breast Cancer by the Long Non-Coding RNA H19

  2017cites this paper
• Targeted delivery of anticancer drugs: new trends in lipid nanocarriers

  2017cites this paper
• The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

  2017cites this paper
• The role of miR-26 a and miR-30 b in HER 2 + breast cancer trastuzumab resistance and regulation of the CCNE 2 gene

  2017cites this paper
• Bioresponsive polymer coated drug nanorods for breast cancer treatment

  2017cites this paper
• Cancer Biomarkers: Important Tools for Cancer Diagnosis and Prognosis

  2017cites this paper
• Utilization of Genomics for Risk Assessment and Molecular Subtyping to Improve Treatment Strategy in Breast Cancer

  2017cites this paper
• CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity

  2017cites this paper
• Continuous Biomarker Assessment by Exhaustive Survival Analysis

  2017cites this paper
• Nanostructures for cancer therapy: from targeting to selective toxicology

  2017cites this paper
• Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro

  2017cites this paper
• Tumor Heterogeneity in Breast Cancer

  2017cites this paper
• Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer

  2017cites this paper
• Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice1

  2017cites this paper
• DNA biosensors based on gold nanoparticles-modified graphene oxide for the detection of breast cancer biomarkers for early diagnosis.

  2017cites this paper
• Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab.

  2016cites this paper
• Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells

  2016cites this paper
• Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells

  2016cites this paper
• Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results

  2016cites this paper
• The Identification and Targeting of Partially-Folded Conformations on the Folding Free-Energy Landscapes of ALS-Linked Proteins for Therapeutic Intervention: A Dissertation

  2016cites this paper
• Alcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow‐up

  2016cites this paper
• A potential peptide vector that allows targeted delivery of a desired fusion protein into the human breast cancer cell line MDA-MB-231

  2016cites this paper
• Breast Cancer: A Molecular and Redox Snapshot.

  2016cites this paper
• Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients.

  2016cites this paper
• Bioresponsive polymer coating on nanoparticles

  2016cites this paper
• Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.

  2015cites this paper
• Two-temperature formalin fixation preserves activation states efficiently.

  2015cites this paper